• Leading-edge provider of prepaid card programs and processing services
• Portfolio includes millions of prepaid debit cards
• Company serves some of the largest pharmaceutical manufacturers in the world

Operating at the cutting edge of innovation, 3PEA International, Inc. (OTCQB: TPNL) is a vertically integrated prepaid card programs and processing services provider, offering solutions for corporate, consumer and government applications. The company is revolutionizing the payments market, catering to a variety of users and industries with innovative solutions and options designed to streamline operations, reduce costs, boost revenue, accelerate product adoption and bolster loyalty.

A trusted and experienced payment processor and provider of prepaid debit card payment solutions, 3PEA International boasts millions of prepaid debit cards within its portfolio. Through its PaySign® brand, the company designs and develops payment solutions, prepaid card programs and customized payment services.

3PEA provides and manages programs for some of the largest pharmaceutical manufacturers in the world, offering co-pay assistance products that are designed to maximize acquisition, retention and adherence of patients. The company also offers corporate incentive prepaid cards, which are transforming the way corporations reward, motivate and engage their existing customers, potential customers, employees and agents.

The customizable prepaid solutions offered by 3PEA enable substantial cost savings and also enhance brand recognition and customer loyalty. The company’s customers include health care companies, major pharmaceutical companies and source plasma providers, large multinationals, prominent universities and social media companies.

Marketed under the proprietary PaySign brand, 3PEA’s solutions are designed to attain measurable results through motivating actions and behaviors. Whether clients are seeking a way to reward consumers, agents, employees or channel partners, 3PEA’s PaySign products provide a solution to meet their specific needs.

For more information, visit the company’s website at www.3PEA.com

• Proposed legislation would remove cannabis from the list of Schedule I controlled substances.
• If successful, it would pave the way for the Canadian company to enter the U.S. market.
• Unique combination of algae and cannabis oils targeting cancer and mental health disease, making Algae Dynamics a lucrative opportunity for investors.

A bill looking to decriminalize marijuana all over the country has recently been introduced in the U.S. Senate, giving fresh hope to legal cannabis businesses that they will be able to expand operations and access federal protections and banking solutions. The bill, titled the Marijuana Justice Act, was introduced by New Jersey Democrat Senator Cory Booker, being designed to reverse the tough federal stance on cannabis and hopefully resolve the ongoing conflict between federal and state laws on cannabis. While still classified as a Schedule I drug on par with heroin, cocaine and LSD at the federal level, marijuana is already legal in 29 states and the District of Columbia either for medical or recreational use. If successful, the bill would allow companies such as Algae Dynamics Corp. (OTCQB: ADYNF) to operate freely in the United States in an entirely legal and regulated market.

The Marijuana Justice Act would remove cannabis from the federal list of drugs on the Controlled Substances Act, according to the Investing News Network (http://dtn.fm/6g9D3). The bill would incentivize states that still oppose marijuana legalization to update their legislation and would also allow prisoners serving a sentence on marijuana possession charges to ask for resentencing.

In a statement, Booker explained that his bill is aimed at helping the current “broken” state of U.S. drug laws. Instead of making communities safer, current drug laws waste billions in taxpayer money, diverting resources from fighting violent crimes and tearing families apart, with an unfair impact on low-income communities and communities of color, the statement said.

Supporters of decriminalization expect tough opposition to the bill, with known opponent Attorney General Jeff Sessions currently seeking Congressional support to remove protections on medical marijuana use at state level and to get a targeted look at MMJ users.

Analysts think the bill is unlikely to pass at this time, but are optimistic that it will stimulate a conversation in Congress on the topic. Cannabis financial analyst Alan Brochstein voiced hope that Senator Booker’s bill would at least get lawmakers to focus on some of the issues the industry is facing – most notably the absence of federal banking support and the lack of sufficient research. But if the bill is successful, it would catapult an already booming industry and open capital markets by removing a series of impediments currently blocking the market, such as access to banking, interstate transport and research, Brochstein said.

The federal decriminalization of marijuana would allow Algae Dynamics Corp., based in Canada but publicly traded in the U.S., to enter the American market with its unique product line that combines the health benefits of algae, hemp and cannabis oils. The U.S. cannabinoid market is expected to reach $2 billion in sales by 2020 and an impressive $50 billion by 2029, according to Statista figures (http://dtn.fm/Bdu6c). This would provide Algae Dynamics with ample opportunities to successfully market its innovative blend of algae and cannabis oils, making the company an ideal target for investors in the fast-growing cannabinoid and cannabis industries. For the time being, the company operates only in Canada, where the marijuana oil extraction market is projected to grow exponentially, from C$1 million in 2015 to approximately C$1.7 billion in 2020, with full cannabis legalization expected in the country in 2018.

Algae Dynamics Corp.’s health and pharmaceutical products primarily target cancer and mental ailments, and the company has already partnered with two Canadian universities to research the use of cannabis oil in these fields. The company has signed a three-year, C$600,000 partnership with the university of Waterloo to research the effects of cannabis oils on pancreatic, colorectal, prostate and breast cancer, and a four-year, C$1 million research agreement with the University of Western Ontario to assess the use of cannabis derivatives for mental health diseases including anxiety, PTSD, depression and schizophrenia.

For more information about the company and its innovative products, visit www.AlgaeDynamics.com

Let us hear your thoughts: Algae Dynamics Corp. Message Board

Global Payout, Inc. (OTC: GOHE) provides comprehensive payment solutions that can be fully customized for virtually any domestic and international organization distributing money worldwide. The company is committed to enabling global access to technology for optimizing financial transactions and delivering a global financial eco-system with top-tier banking institutions and the highest level financial technology partnerships.

Today, more than ever before, commercial enterprises and government institutions need powerful financial technology solutions that have the flexibility to deliver innovative customer centric services and drive operational efficiency gains throughout the organization. The Global Reserve Platform is Global Payout’s fully configurable “banking-in-a-box” web-based platform that can fulfill the front-to-back office processing requirements of domestic, foreign exchange and international payment service providers. This platform is designed to improve work flow, operational efficiencies, and global financial management for enterprises operating across the globe.

The Global Reserve Platform can manage practically any financial product, including core and traditional banking products, online banking, card management, mobile wallets, merchant payment processing, biometric payments and authentication management, bill payments and P2P payments, international remittances, government benefits management, loans management, FOREX, and SWIFT / ACH / SEPA payments. Powered by the Global Reserve Administrative module, the platform can be customized for enterprises across a multitude of business sectors.

Investment in financial technology (FINTECH) companies has grown dramatically in recent years with the role of today’s banks shrinking and demand for improved financial solutions continuing to rise. As the industry has continued to expand rapidly, Global Payout’s management team has directed its focus on identifying the most promising market sectors with FINTECH needs. The four core areas selected are logistics, small and medium enterprises (SME), banking and travel.

In 2015, Global Payout introduced MoneyTrac Technology Inc. as a majority owned subsidiary to more effectively focus on the development of financial technologies that specifically address many of the challenges that enterprises in a variety of alternative and “high-risk” market sectors are faced with in processing financial transactions. Powered by Virtu Network Solutions, the MoneyTrac Technology platform is one the most configurable and intuitive financial technology platforms available to alternative and “high-risk” enterprises and provides them with solutions that effectively manages everything from pin debit and virtual currency, to compliance and cash flow logistics.

With the global economy constantly becoming more diversified and connected, Global Payout is well positioned with the technology software solutions its team has developed to address many different needs worldwide. Management has committed itself to exploring and identifying every avenue possible for further establishing itself as a recognized leader in FINTECH solutions.

For more information, visit the company’s website at www.GlobalPayout.com

Let us hear your thoughts: Global Payout, Inc. Message Board

• Incubator for developers of mobile apps
• Digital game industry continues to grow
• Mobile app development across Apple, RIM, Google and Microsoft Platforms

If you think that movies are big business, you’re right. Then what would you say about the digital game industry, which by most accounts is twice or three times as large? Out of a global population of some 7.5 billion, about 2.2 billion (29%) play ‘video’ games. That’s good, since, according to one academic report, ‘playing video games can boost brain power’. So playing digital games is smart as well as fun, which is why AppSwarm, Inc. (OTC: SWRM) is planning to increase the choice that gamers have. The innovative company is an incubator for the development of mobile apps, which include digital games. With a fast growing portfolio, one of its games may soon be playing at a home near you.

Even though global box office revenues are expected to rise from $38 billion in 2016 to $50 billion by 2020, according to The Statistics Portal (http://dtn.fm/fD3T3), it will be dwarfed by the global digital game industry, expected to generate about $109 billion in revenues in 2017, increasing from $100 billion in 2016. ‘Digital game revenues will account for $94.4 billion or 87% of the global market’, according to New Zoo (http://dtn.fm/f7GoS). Mobile is expected to be the most lucrative segment, with smartphone and tablet gaming growing 19 percent year on year to $46.1 billion, claiming 42 percent of the market. By 2020, mobile gaming may represent more than half of the total games market.

To capitalize on these exciting trends, AppSwarm was established in 2012 as an incubator for digital app developers. Since then, the company has been engaged in acquiring a range of apps for all forms of devices. AppSwarm offers complete, end-to-end services for mobile application development across all major platforms including Apple iPhone, RIM’s BlackBerry, Google’s Android, and Microsoft’s Windows Mobile. The company has agreements in place with all of the major application stores and is able to assist with application development and act as a strategic partner to facilitate increased visibility, thus allowing most small firms, young entrepreneurs and application developers the resources they otherwise would not have to market their applications effectively.

Games are one segment of the app market that AppSwarm is intensely involved with. Most people play digital games to have fun and relax, but details, reported by Science Daily (http://dtn.fm/Z22Bk), of a study conducted by a team at Queen Mary College, University of London show that video games may be less of the idle pursuit that they are often blamed to be. The researchers found that ‘certain types of video games can help to train the brain to become more agile and improve strategic thinking.’ Playing some games increases ‘cognitive flexibility’, our ability to adapt and switch between tasks and to think about multiple ideas at a given time to solve problems. Cognitive flexibility, it seems, enhances creative problem solving and our ability to ‘think outside the box’.

AppSwarm’s current game portfolio includes Turtles, Huh?, which is ranked as the #1 iOS family games app in five countries, ranked in the top five iOS family games app in 22 countries and ranked in the top 10 iOS family games app in 44 countries. Another game, Avenging Soldiers, is a battle game made with stunning quality visuals, precise controls and advanced physics. Still another, Dead Uncleansed, is an exciting “Tower Defense” game set in a near future world where an evil dictator has manufactured and released a virus. The virus is turning the “infected” into evil zombies that are hell-bent on destruction and killing everything in their path, just the sort of game to play before turning in for the night. And then there is Soccers, a soccer game that you can actually play soccer in. With the 21st FIFA World Cup scheduled for Russia next year, AppSwarm already has skin in the game.

For more information, visit the company’s website at www.App-Swarm.com

• Unclear whether amendment will survive in final appropriations bill, but Congressional vote sends message to Attorney General Jeff Sessions
• CIIX is expanding in global market with online cannabidiol store in Shanghai, China, and brick-and-mortar unit to open in San Gabriel, California
• Consilium Global Research estimates that CIIX will outperform cannabis market to achieve revenues of $14.8 million by FY 2020

ChineseInvestors.com, Inc. (OTCQB: CIIX) and other cannabis companies were overjoyed by the July 27 affirmative voice vote by the Senate Appropriations Committee to approve an amendment to a “2018 Commerce, Justice and Science Bill” that bars the federal government from using federal funds to investigate medical marijuana cases within states that have legalized medical marijuana. It is unclear whether the Rohrabacher-Blumenauer amendment will be part of the final appropriations bill.

However, the Senate sent Attorney General Jeff Sessions a clear message in passing this amendment, defying his letter to Congress urging that the amendment not be passed. A total of 29 states and the District of Columbia have made medical marijuana legal, according to ProCon.org (http://dtn.fm/99mOe). In addition, eight states and DC have made recreational use of marijuana legal. To CIIX and other legal cannabis companies, that vote was seen as an important victory enabling them to “solidify their footholds in the marketplace,” according to one published research article (http://dtn.fm/Z7bzM).

CIIX has a goal of becoming the primary Chinese medical cannabis publicly traded company. To that end, the firm has been aggressive in focusing on research and development as well as distribution of cannabidiol-based (CBD) products globally to the Chinese-speaking population.

In China, sales of CBD is legal, while marijuana is not. CIIX has an online store in the free trade zone of Shanghai selling CBD-based products. It has also established a wholly owned subsidiary, CBD Biotechnology Co. Ltd., which plans to market the CBD Magic Hemp Series. The company has filed with the China Food and Drug Administration (CFDA) for this line of non-industrial hemp-infused skincare products. The line is anticipated to launch in August/September 2017.

CIIX believes itself to be a first mover in China, a consumer market of two billion consumers. In other moves, it has incorporated CBD Technology in British Columbia, Canada. CBD Technology will distribute, research, and sell hemp-based CBD plus beverages and food products.

In in its home market of San Gabriel, California, CIIX is preparing to open its first brick-and-mortar store to, in part, distribute its new OptHemp health products line. It will be among the first stores to sell the line.

Consilium Global Research projects that CIIX will reach $14.8 million in revenue by FY 2020 and said that the CBD market will grow by a compound annual growth rate (CAGR) of 80% to $2.1 billion by 2020 (http://dtn.fm/L7hGB). The research firm believes that CIIX will outgrow the market with a 100% CAGR in that time period. It also believes that CIIX has an advantage due to the fact it is well ingrained with native Chinese speakers globally.

For more information, visit the company’s website at www.ChineseInvestors.com

Let us hear your thoughts: ChineseInvestors.com, Inc. Message Board

• Bright Future for LTO Tape Tech, QBAK a Sector Pioneer
• N2Power Upside Bullish Amid Burgeoning Gaming Market
• 12 Months of Positive Cash Flow, Solid Long-Term Fundamentals

Qualstar is one of the oldest names in data storage, with a track record stretching back to the company’s founding in 1984 as one of the first tape drive developers for PC and workstations. Having developed Linear Tape-Open (LTO) technology alongside industry giants HP (NYSE: HPQ) and IBM (NYSE: IBM) in 1998, QBAK is a storied outfit that famously helped offer a clear and viable choice in earlier days of the computing revolution when there was a great deal of confusion due to an increasingly complex tape storage market. And the company is now also known for their N2Power subsidiary’s superbly designed, highly efficient, power-dense, and ultra-small power supply units (PSUs), which are utilized in a wide variety of equipment across numerous industries.

LTO Tape, a Potential Answer to Tightening Cloud Storage Margins

Now, investors may not be aware of this, what with all the retail consumer-directed ballyhoo over the latest solid state drives, but seemingly ancient tape drive technology is actually pretty compelling. Particularly when it comes to handling archival data and backups, where the latest generation of LTO-7 drives have proven themselves in independent testing to be excellent solutions. SSG-NOW ran some tests in March on Ultrium cartridge (LTO tape specification optimized for capacity and performance) based LTO-7 tapes, finding them not only ready for use in a production environment, but easy to use thanks to the Linear Tape File System (LTFS) making them appear as just another mounted drive. Generation 8 of LTO Ultrium is slated to more than double storage space to 32 terabytes, with more than a 57 percent increase in speed, up to 1,180 megabytes per second.

Of the big three industrial-scale cloud storage players, Google (NASDAQ: GOOGL; GOOG) is the only one to really talk publicly about using tape in its storage architecture. Microsoft (NASDAQ: MSFT) often touts the tech, but is very hush-hush about its Azure platform build. And Amazon (NASDAQ: AMZN) is apparently still living in the 90’s, when tape first fell out of favor, largely due to the emergence of cheaper and bigger disk drives, as well as problems associated with the terrible backup software they had back then.

The truth is that LTO, especially given the future roadmap for the tech (size and speed nearly doubling each generation), represents an ideal solution when it comes to reliability and performance in archival, backup, and storage tasks. Especially amid the rise of big data. And LTO is a solution which is also low-cost, preserving and enhancing the margins of the cloud business model, as we leap into the abyss of requiring zettabytes (one sextillion bytes) of storage in order to handle all the data we are producing. The increasingly rapid emergence of a world of connected, intelligent devices (Internet of Things, or IoT), and the big data analytics necessarily associated therewith, will put increasing pressure on cloud vendors to migrate into high-performance, low-cost solutions like tape.

QBAK Superbly Positioned to Exploit Underlying Market Dynamics

Not only do the kinds of tape solutions which Qualstar is known for have the power to save the economics of the post-zettabyte cloud model, these tape-based storage solutions also happen to represent easy access to an ideal cloud seeding workaround. This allows companies to bypass slow, contemporary networks when it comes to getting their data to the cloud. Due to an increasingly prevalent method where data is mirrored onto physical media like a tape drive and then physically sent to the cloud storage company’s server farm, cloud seeding via couriers is quickly becoming standard operating procedure for many.

Notably, there are several other key factors that set tape storage technology out as clear winner moving forward. Native write speeds of 300 MBps or greater (SSG-NOW was clocking rates of 750 MBps on readily-compressible documents like Word files and PDFs) is one of the greatest reasons. The Linear Tape File System’s (LTFS) super easy backup and restore workflow is another key aspect, which is inherently similar to disk-to-disk mirroring, but without the need for special backup software.

Considering $203 billion plus estimates for the big data and analytics market by 2020 (a nearly 12 percent CAGR), Simi Valley-headquartered QBAK looks to be in an extremely favorable position. Qualstar’s Simply Reliable™ XLS architecture is one of the most attractive solutions on the market today for growing data centers, due to proven flexibility, modularity, and reliability. Using self-contained, standalone LRMs (library resource modules) as the core, this architecture is also easily expandable for big capacity via MEMs (memory expansion modules).

The strong data management and storage offerings from this company, like the XLS-89000 MEM unit, will no doubt see Qualstar slicing off an ever larger slice of a growing pie, as cloud vendors awaken to the performance, scalability and cost benefits of such LTO architectures. The XLS-89000 boasts an incredible 16.13 petabytes of storage at maximum compression using LTO-7 (6.45 PB native), can hold 1,075 tape cartridges, and can be easily “daisy chained” with either type of XLS enterprise library system (XLS‑832700 or XLS‑8161100). This allows for field expandability up to 7,500 cartridges.

It is important for investors to understand how this easy extensibility and scalability translates directly into ease of use for operators, making these well-thought-out designs as intuitive, as they are powerful. QBAK’s patented Compass Architecture carousel technology allows for ridiculously high-density storage of 758 terabytes (uncompressed) per square foot, while still enabling the robotic tape handler to function in a gentle-motion profile, leading to improved reliability from this vital system. Whether a company is just starting out and wants a single, automated, high-capacity rack mountable tape library like the RLS-8350 (expandable by up to 8x via RLS-85120 modules), or is ready to enter the big leagues with a fully-expanded XLS setup, Qualstar is a one-stop shop for robust storage.

N2Power a Potential Sleeper Hit

The increasing probability of data ending up on tape is an important trend for investors following the growth of the data market – and it holds true whether a company is doing backup and archival in-house, or handing off to a cloud service. This is very bullish for QBAK’s enterprise library system business, but the company’s N2Power subsidiary may hold even more promise. N2Power has developed a very healthy market for the company’s industry-spanning array of ultra-small, highly efficient power supplies, which feature some of the highest power densities on the market. The diminutive power supplies are green by design, with up to a 93 percent efficiency rating, a lower heat generation profile, and most units require little or no forced air cooling.

With a strong footing in various markets like gaming, IT (both PSUs and enclosures), medical, light industrial and high-power equipment, N2Power has accrued quite the reputation for its beefy little PSUs (power supply units). Leading to a strong foundational market position and deals like the recently announced (July 25) $0.6 million the company landed in multiple orders for PSUs set to ship over the next five months or so, from an existing, prestigious gaming industry customer. The global casino gaming market is set to expand at 10.16 percent through 2021 according to a recent report from Research and Markets. The US casino gaming market represents the lion’s share of the space and is set to hit $93 billion by 2020. And the broader global digital gaming market (minus mobile) is around $62.8 billion this year and is on-track to grow as a whole by around 6.2 percent CAGR through 2020, on the strength of continued user adoption rates, and factors such as eSports and VR.

This is a great cultural backdrop and market environment for QBAK’s N2Power, which has established itself as a favored provider of feature-rich gaming PSUs to a variety of customers, ranging from some of the top casino gaming and ATM machine developers, to LED/lighting, and other applications. The ultra-dense, efficient power supplies N2Power provides to OEM designers are much sought after, not only because they reduce thermal load and cooling requirements, which is cheaper on energy, but also because the greater density frees up crucial machine real estate to make more room for other components. N2Power makes some of the tiniest, most reliable 125W to 500W AC-DC PSUs in existence today.

Strong Bottom Line Makes a Nice End Cap

It’s little wonder then that QBAK’s Q2 results showed YoY net income up 116 percent, in part on strong sales growth, as well as product expansion in the N2Power unit. With a strong balance sheet and no debt, such data points as the 6.5 and 6.9 percent increases (respectively) in gross profit margins for the three- and six-month periods (compared to the same period in 2016) are something which should really stand out to investors as a sign of the company’s fitness. Even before taking note of a 22.8 percent reduction in operating expenses over the six month period.

Take a closer look, visit http://www.qualstar.com/index.php

• Strategic acquisitions driving company growth, offering unique opportunities for investment
• Company completed Cranbury International acquisition, expanding portfolio and international reach
• Product roster further expands with VR training materials and 3D animations

Innovative EdTech company ProBility Media Corp (OTCQB: PBYA) is solidifying its position on the e-learning and training market via a series of recent acquisitions and new service and product offerings. With a declared goal of building the first full-service career advancement and training brand for skilled trades, ProBility is offering a combination of training and educational materials with virtual reality-based products for modeling training and 3D animation to an expanding international market.

The Houston, Texas-based company has just completed the acquisition of Vermont-based provider of education and training materials Cranbury International, thus gaining access to a wide range of new products destined for government institutions and private sector markets in several countries, including Brazil, Colombia, Trinidad, Mexico and many others. Aside from increasing its international reach and customer base, the acquisition will allow ProBility to introduce several of its own e-learning and virtual reality programs to new markets, at the same quality standards Cranbury has been adhering to since its creation in 2010.

Virtual reality has been a major component of ProBility’s product roster for a while, being used successfully for crane operator training, and the technology’s role is set to increase further as a result of ProBility’s joint venture with Industrial3D Corp., a provider and developer of 3D modeling, 3D animation and interactive media. Under the name ProBility Immersive Technologies, the joint venture specializes in creating interactive media and virtual reality content for ProBility’s current educational offerings, as well as for any custom products designed for clients who want to conduct their training in-house.

The joint venture has enhanced ProBility’s portfolio with over 200 3D animations targeting the industries it already serves, such as energy, medical manufacturing, engineering, etc., and it also enables the company to significantly expand its comprehensive offering of career advancement, training and compliance materials for more than 60 skilled trades.

The move came shortly after ProBility took a larger share of the educational market for the electrical contractor industry, estimated at $130 billion, following the acquisition of W Marketing, Inc., a provider of National Electrical Codes to the construction and electrical industries with a vast library of educational courses and exam preparation materials. In addition to strengthening ProBility’s financial position, the acquisition will allow the company to become one of the largest wholesale providers of National Fire Protection Association electrical codes in the United States.

The company has also expanded into the field of safety and security with the launch of an online training place, the ProBility Safety Academy – the result of a joint venture with Range Guard and Investigations Vice President Jonah Nathan. The Texas-accredited academy offers training, exam materials and courses for various security and safety fields including police science, public safety, private security, private investigation and criminal justice.

ProBility’s strategic acquisitions policy is making the company an appealing opportunity for investors in the e-learning and training space who are looking for ways of tapping into a growing organization serving dozens of industries and helping bring skilled trades and businesses into the 21st century. With an impressive portfolio of training and education programs, both online and in print, the company aims to change the landscape for small and medium businesses by offering them access to quality training materials typically only available to enterprise firms. Through its ever-growing product offerings and its acquisition policy, ProBility is set to position itself as a market leader in the e-learning sector and a high-quality source of testing, education and career advancement services.

For more information, visit the company’s website at www.ProBilityMedia.com

• Current telemedicine model is fragmented with little to no up sell
• Millions of Americans live in areas with little to no comprehensive health care
• MIHI building nationwide telemedicine network, making MIHI sole practitioner to millions

An estimated 80 million Americans live in rural areas where access to medical services is extremely limited. Identified as Medically Underserved Areas by the government, these regions suffer from a chronic shortage of not only primary care physicians but, even more critically, specialty care physicians. Targeting these medically underserved areas, Medical Innovation Holdings, Inc. (OTC: MIHI) intends to deliver much needed medical care while simultaneously developing the foundation of its unique business model.

Utilizing telemedicine to connect specialty physicians to diverse rural areas, MIHI is committed to expanding and disrupting the traditional telemedicine business model, building a national network of physicians and patients, and vertically integrating multiple health care-related products and services across multiple platforms throughout its entire network. Because specialists are primarily based in urban areas, rural patients do not have direct access to these specialists and are forced to travel great distances, wasting time and money to get the care they need.

The company’s business model provides much needed specialty practice medical services to underserved rural patients in the setting of their primary practice provider. It also provides the rural physician with administrative support, additional income through more product and service offerings, and the ability for the rural practice to grow exponentially while providing access to specialist practitioners.

The company’s proprietary telemedicine platform brings together multiple modalities of telemedicine to create a virtual multi-specialty practice within a rural primary clinic practice. The business model is designed to greatly increase the access to specialty providers, including, neurology, dermatology, ear nose and throat, tele-stroke, management of high-risk pregnancy, psychiatry, dermatology, endocrinology, pediatrics, cardiology, nephrology, pulmonology, OBGYN, maternal and fetal, and others.

With the intent of driving shareholder and market value, MIHI is creating various subsidiaries that will become the foundation designed to both service and support its network of medically underserved markets. MIHI has already created both 3Point Care and BKare Diagnostics as distinct revenue drivers. 3Point Care is a management service organization (MSO) with an exclusive contract relationship with TeleLife MD to provide telehealth services to MIHI’s marketplace. BKare Diagnostics is a full scale provider of high quality laboratory and pharmaceutical services that supports the company’s entry into medical lab services, medical devices, and nutraceuticals.

With the ability to provide a vast array of health care-related services on its various technology platforms, the company intends to create a comprehensive health care-centric business ecosystem where multiple products and services can be offered. As the company expands its unique business model into a large national footprint, a nationwide network of underserved patients will receive much needed services and, in essence, make MIHI a sole practitioner and product provider to a large swath of the population.

To effectively service such a large and diverse population across such a vast geographical area, the company has identified multiple products and services such as nutraceutical supplements, CBD products, OTC homeopathic medicines, lab services and traditional pharmaceutical products to feed into the network and meet the demands of this new market. The scope of products and services is limited only by medical needs and opportunities with the company’s network.

Since any pretense of competition is primarily based on the current dysfunctional large hospital or holding company medical model, the company intends to expand unabated throughout the United States and transform the status quo or telemedicine.

For more information, visit the company’s website at www.MedicalInnovationHoldings.com

• Lexaria Bioscience Corp. featured in a Technical420 article praising the company’s recent developments
• Lexaria is improving and strengthening patent portfolio; 19 patent applications are pending in more than 40 countries
• Company executes partnership with NeutriSci International; joint venture allows LXRP to enter Asian market

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP), an innovative company licensing proprietary technology for the delivery of bioactive compounds including cannabinoids, is a “plant-to-bloodstream” company expected to draw investors in the cannabis marketplace. Lexaria has patented and licenses a novel delivery system that infuses organically sourced hemp oil into the molecules of other substances.

Cannabidiol, noted for its anti-inflammatory, anxiolytic, antiemetic and antipsychotic effects, is just one of several compounds targeted by Lexaria for its unique oral ingestion technology, which allows more efficient delivery of bioactive substances via oral ingestion without the need for unhealthy inhalation or the addition of sweeteners commonly used to mask bitter tastes. Non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and vitamins are among the substances targeted by Lexaria’s new delivery method.

A recent article in Technical420 (http://dtn.fm/C5gjS), a provider of research and analysis of cannabis stocks, praised the company for several positive developments over the past few months.

Lexaria has 19 patent applications filed and pending in more than 40 countries worldwide. The company strengthened its intellectual property portfolio with its first U.S. patent, issued in October 2016. The patent protects Lexaria’s intellectual property for infusion of cannabinoid compounds in edible products. Lexaria’s unique process improves the taste and bioavailability of cannabinoid food ingredients.

Another strong development is Lexaria’s joint venture with NeutriSci International (TSX.V: NU), a Canadian public company, to produce and sell a line of healthy edible cannabinoid products. The two companies will produce a line of cannabinoid mouth-melt products using Lexaria’s technology and NeutriSci’s proprietary pterostilbene tablet. Pterostilbene is an antioxidant that’s chemically similar to Resveratrol – a natural compound found primarily in blueberries and Pterocarpus marsupium heartwood, according to the U.S. National Library of Medicine (http://dtn.fm/5BkqA).

The joint venture will operate as Ambarii Trade Corporations, and initial operations will be funded equally by Lexaria and NeutriSci. AMbarii’s plans include securing licensees in Canada, California and Colorado to produce mouth-melt products containing THC.

Lexaria is also venturing into the Asian market, as noted by the Technical420 article. Ambarii has entered into an LOI with Naturally Splendid Enterprises Ltd. (TSX.V: NSP) for production and distribution of the company’s sublingual full spectrum cannabidiol tablets in Japan and South Korea. With a population of 127 million, Japan is one of the world’s largest markets, and hemp oil containing cannabidiol is already legal in Japan. South Korea, with a population of 50 million, is expected to open its markets to hemp oil-sourced cannabidiol soon.

Lexaria will begin in vitro absorption studies to quantify improvements in absorption in human intestinal tissue and will conduct animal studies on whole-body reactions to the rapid and efficient delivery of cannabinoids, vitamins, NSAIDs and nicotine. Edible nicotine products could allow a healthier alternative to smoking, patches and nicotine gum. The article points out that the company’s R&D budget is fully funded from existing capital.

Lexaria has an improved cash position and an attractive valuation, the Technical420 article states, due to improved balance sheets and a much smaller warrant overhang. The company raised more than $1.7 million in April, and, from November 2016 through May 2017, the company raised more than $4 million in equity. Technical420 is “favorable” on these developments and expects to see significant advancement by Lexaria Bioscience.

For more information, visit the company’s website at www.LexariaEnergy.com

Let us hear your thoughts: Lexaria Bioscience Corp. Message Board

• Drug candidate for top cause of death in the United States
• Genetically-targeted therapy increases chances of recovery
• Interim efficacy analysis soon to be conducted by the Data Safety Monitoring Board

Atrial fibrillation affects up to six million people in the U.S. The condition, if untreated, can lead to blood clots, stroke, heart failure and other heart-related complications, but many medications currently in use to treat it come with worrying side effects, perhaps because of their one-size-fits-all approach. In an effort to mitigate the unwanted, unintended action of these agents, ARCA Biopharma, Inc. (NASDAQ: ABIO) is applying a precision medicine approach, developing genetically-targeted therapies for cardiovascular diseases, as it works to bring its lead candidate for atrial fibrillation, Gencaro™, to market. The company believes that by tailoring medical treatment to the individual genetic characteristics of patients, more effective therapies will be enabled, patient outcomes will be improved and health care costs will go down.

Atrial fibrillation (AFib) is the most common kind of heart arrhythmia, a condition where the heart beats too fast, too slow, or in an irregular fashion. In a heart suffering from AFib, the regular pumping action of its upper chambers, the atria, is impaired. As a result, blood flow to the lower chambers, the ventricles, is impeded. AFib increases a person’s risk for stroke by four to five times compared with people who do not have it, and strokes caused by complications from AFib tend to be more severe than strokes with other underlying causes. AFib causes 15%–20% of ischemic strokes, which occur when blood flow to the brain is blocked by a clot or by fatty deposits called plaque in the blood vessel lining.

According to the Centers for Disease Control and Prevention (http://dtn.fm/sCD06), “more than 750,000 hospitalizations occur each year because of AFib… (and) the condition contributes to an estimated 130,000 deaths each year. (In addition), the death rate from AFib as the primary or a contributing cause of death has been rising for more than two decades.” AFib costs the United States about $6 billion each year, and medical costs for people who have AFib are about $8,705 higher per year than for people who do not have AFib.

Current treatments for AFib include drugs for heart rate control, drugs for heart rhythm control, and blood thinners. These medication, however, give rise to a plethora of side effects, including breast enlargement, diarrhea, low blood pressure, and heart failure, as well as psychological problems. One class of drugs that controls heart rate is known as beta-blockers; drugs of this type work by reducing heart rate, an example of which is ARCA’s lead candidate, Gencaro.

Gencaro (bucindolol hydrochloride), is a pharmacologically unique beta-blocker and mild vasodilator, now under evaluation in a clinical trial for the treatment and prevention of recurrent AFib in heart failure patients with reduced left ventricular ejection fraction, or HFREF. The company believes that Gencaro’s mechanism of action (MOA) differs from other beta-blockers because of its sympatholytic (norepinephrine lowering) and inverse agonism (inactivation of constitutively active receptors) properties. Genetic variations in receptors in the cardiovascular system of the general population vary, and these variations are thought to be a factor in how well patients respond to treatment. With Gencaro, ARCA has developed a formulation which interacts positively with a genotype, beta-1 389 arginine homozygous, found in approximately 50 percent of the U.S. population. Consequently, a Gencaro regimen promises a reduced range of side effects for a larger population of patients.

In June 2017, ARCA announced database lock for the GENETIC-AF interim efficacy analysis to be conducted by the trial Data Safety Monitoring Board (DSMB). Locking or closing a database ensures that no unauthorized or unintentional changes are made after the final data entry, check-up, and analysis. GENETIC-AF is a phase 2B/3 double-blind, clinical superiority trial comparing the safety and efficacy of Gencaro to an approved drug, TOPROL-XL, for the treatment and prevention of recurrent AFib in heart failure patients with reduced left ventricular ejection fraction (HFrEF). The company expects to announce the DSMB’s recommendation based on this interim analysis in August 2017. The Gencaro development program was previously granted Fast Track designation by the U.S. Food and Drug Administration (FDA).

For more information, please visit www.ARCABio.com